Research programme: beta lactamase inhibitors - LegoChem Biosciences/Geom Therapeutics

Drug Profile

Research programme: beta lactamase inhibitors - LegoChem Biosciences/Geom Therapeutics

Alternative Names: GT-055; LCB18 0055

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LegoChem Biosciences
  • Developer Geom Therapeutics; LegoChem Biosciences
  • Class Antibacterials; Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 20 Jul 2018 Antimicrobial data from preclinical trial in Gram-negative infections presented at ASM Microbe 2018 (ASMM-2018)
  • 27 Sep 2017 Beta lactamase inhibitor programme licensed to Geom Therapeutics Worldwide except South Korea
  • 27 Sep 2017 Preclinical trials in Gram-negative infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top